Adjuvant Sutent [sunitinib] following chemotherapy, radiation and surgery for esophageal cancer, a phase II trial (ASSET)
Phase of Trial: Phase II
Latest Information Update: 10 May 2017
At a glance
- Drugs Sunitinib (Primary) ; Cisplatin; Irinotecan
- Indications Adenocarcinoma; Oesophageal cancer
- Focus Therapeutic Use
- Acronyms ASSET
- 03 May 2017 Status changed from active, no longer recruiting to completed.
- 07 Mar 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.
- 07 Mar 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov.